Evotec SE announced today that the Company has made a strategic equity investment in Tubulis GmbH by participating in the company’s Series B financing round. Based in Munich, Germany, Tubulis specialises in the development of antibody drug conjugates (“ADCs”) by leveraging a set of proprietary technology platforms to develop these highly targeted therapeutics against solid tumours. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-makes-strategic-equity-investment-in-antibody-drug-conjugate-specialist-tubulis-6168